JTX-1484

JTX-1484 is an investigational **monoclonal antibody** developed by **Jounce Therapeutics** for cancer immunotherapy. It is designed to antagonize **leukocyte immunoglobulin-like receptor subfamily B member 4** expressed on suppressive myeloid cells in the tumor microenvironment, also referred to as **ILT3** in company and conference materials. By blocking this myeloid immune checkpoint pathway, JTX-1484 is intended to reprogram immunosuppressive myeloid cells, reduce tumor-associated immune suppression, and enhance T-cell priming and effector function. Publicly available information indicates the program remained in **preclinical IND-enabling development** for **neoplasms** and had not yet advanced into registered clinical trials.

Other names

anti-LILRB4 antagonist antibodyanti-LILRB-4 antagonist antibodyanti-LILRB 4 antagonist antibodyanti-ILT3 antagonist antibodyanti-ILT-3 antagonist antibodyanti-ILT 3 antagonist antibody